focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Wild,
In context, bad news would have been Covidity doesn't work. Good news would have been Covidity works and we have found a partner.
I guess the validation of immunobody and Avidimab is actually very good news but beyond the comprehension of the wider market.
Wait for the big reveal.
There seems to be a pattern:
Essential news - new chairman.
Negative news - Issue of equity.
Neutral news - Covidity works but no partner yet.
Next news should be stonking- Modi works (plus deal?)
Cleaner,
Yes, rather a muted response SP wise given the news. I can understand people being neutral on the potential commercialisation of Covidity but the validation of immunobody and Avidimab is huge in the context of Scancell's pipeline.
Two,
".after the bell. Those in the know care to confirm if it's a buy?"
Yes, I can confirm it is a buy, or possibly a sell.
I makes little difference either way. Over time, the volume of buys will equal sells. If it was a buy, there will be an equivalent number of sells. If it was a sell there will be an equivalent number of buys.
So relax and chill.
Crumbs,
"I'm not here for Covidity... is anyone else?"
Well I'm not either. There's nothing built into the current SP for Covidity but that won't stop the share being marked down on the hint of a bit of negative news.
Crumbs,
I'm not predicting a 10p drop, although I can't entirely rule it out.
I was responding to violin's comment stating he expects a big uptake following the Covidity news. I agree, if it's good there will be buying , if it's bad the sp will drop and there will be buying at the lower price (whatever that turns out to be)
Crumbs,
"What's bad"?
There are several possible scenarios.
The good:
We are pleased to report the Covid trial was a success and we have found a partner who will take it through trials and to market.
The bad (or not so good):
We are pleased to report the Covid trial was a success and we are still seeking a partner
We are pleased to report the Covid trial was a success but we will not be taking it further.
Unfortunately the Covid trial showed no greater immunity than vaccines already on the market.
So if the news is good the SP will rise.
If the news is bad, the SP will fall and then recover.
If the MODIFY news comes first, the impact of any bad news on Covidity will be lessened.
AIMO of course.
" I think that we will see a marked uptake in interest post the Covidity RNS."
(Posted by Violindog)
Yes, if the CovidIty news is bad and the share drops 10p then I do expect a big uptake buying into Modi, Scib, Avidimab and Glymab at a hefty discount.
Ciaskin,
You may well be right, who knows what it was for. My thinking was "what has changed?"
Nothing as far as I know on Glymab but possibly it has on Covidity. If they sell it off outright, there would be no need for a separate company (if ever there was).
I'm surprised that they are winding up Zakari. They could have just kept it dormant - it would only cost the annual filing fee. That would have a least stopped us speculating what is was for and what's changed.
Cleaner,
Just because the vaccine's status is "designed" does not mean it's any good. We won't know that until the data has been analysed and results published. Even then, it will depend on what potential partners think of the results. Are they that much better than the competition?
As you say, the company have no intention to invest any more time on development so if the results are not extremely good or a partner can't be found then that's the end of the road for Covidity I'm afraid.
The winding up of Zakari might be a bit of a clue where this is going. It will be sold off for a nominal fee or scrapped (IMO). I'm not too worried about that, the dual in the crown is Moditope, ably backed up by Glymab.
Konar,
"strictly speaking we only have 2 trials in progress, not 3. Covidity trial has concluded."
No, the Covidity trial is still very much active. It is just that recruiting is complete that's all.
We still eagerly await results.
WTP,
I'm afraid that the "doom squad" are a figment of yours and a couple of others over active imagination. Everyone invested here wish Scancell success and are optimistic that will happen. Some people take a more circumspect view than others, that's all.
Like you, I managed to add earlier in the week and this morning sub 20p.
C11,
" It’s reasonable to think that the newsflow tap may well now be turned on in Feb."
Yes, quite reasonable. I remember when LD was appointed CEO there were several news releases over the following month.